Suppr超能文献

玻璃体内注射贝伐单抗后增殖性糖尿病视网膜病变患者玻璃体内血管内皮生长因子、碱性成纤维细胞生长因子及纤维化的变化

Changes in vitreous VEGF, bFGF and fibrosis in proliferative diabetic retinopathy after intravitreal bevacizumab.

作者信息

Li Jiu-Ke, Wei Fang, Jin Xiao-Hong, Dai Yuan-Min, Cui Hu-Shan, Li Yu-Min

机构信息

Department of Ophthalmology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, Zhejiang Province, China.

出版信息

Int J Ophthalmol. 2015 Dec 18;8(6):1202-6. doi: 10.3980/j.issn.2222-3959.2015.06.22. eCollection 2015.

Abstract

AIM

To evaluate the relationship between intravitreal bevacizumab (IVB) treatment and the levels of vitreous vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and vitreous-retina surface fibrosis in patients with proliferative diabetic retinopathy (PDR).

METHODS

This study was a prospective, open-label, controlled, randomized clinical trial. Sixty-eight eyes of PDR patients (n=53) and macular hole patients (n=15) were enrolled in this study. Thirty-four eyes of the PDR patients received IVB before vitrectomy. Twenty-three of the 34 PDR patients received IVB treatment 5d before vitrectomy (subgroup a), and 11 of the 34 PDR patients received IVB treatment greater than 2wk prior to vitrectomy (subgroup b). Nineteen of the PDR patients did not receive IVB treatment at any time prior to vitrectomy. The levels of bFGF and VEGF in vitreous samples were measured using enzyme-linked immunosorbent assay (ELISA) and the degree of vitreoretinal fibrosis was characterized using clinical data and data obtained intra-operatively.

RESULTS

In PDR patients, VEGF and bFGF levels were significantly increased compared to non-PDR (control) subject's eyes (P<0.01). In PDR patients, vitreous VEGF levels were significantly decreased following IVB treatment compared to PDR patients that did not receive IVB treatment (P<0.01). The degree of vitreoretinal fibrosis was significantly increased in subgroup b compared to subgroup a(P<0.05) and to patients that did not receive IVB (P<0.05). Vitreous bFGF levels were significantly greater in subgroup b than subgroup a (P<0.01) or in patients who did not receive IVB treatment (P<0.05). A Spearman's rank correlation test indicated that higher levels of vitreous bFGF, but not VEGF, correlated with the degree of vitreoretinal fibrosis.

CONCLUSION

We found that bFGF levels increase in PDR patient's vitreous after IVB treatment longer than two weeks prior to vitrectomy and correlated with the degree of fibrosis after IVB treatment. These findings suggest vitreous fibrosis is increased in PDR patients after IVB treatment may be due to increased levels of bFGF.

摘要

目的

评估玻璃体内注射贝伐单抗(IVB)治疗与增殖性糖尿病视网膜病变(PDR)患者玻璃体内血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)水平及玻璃体 - 视网膜表面纤维化之间的关系。

方法

本研究为前瞻性、开放标签、对照、随机临床试验。纳入68只PDR患者眼(n = 53)和黄斑裂孔患者眼(n = 15)。34只PDR患者眼在玻璃体切除术前接受IVB治疗。34例PDR患者中,23例在玻璃体切除术前5天接受IVB治疗(a组),11例在玻璃体切除术前超过2周接受IVB治疗(b组)。19例PDR患者在玻璃体切除术前未接受任何IVB治疗。采用酶联免疫吸附测定(ELISA)测量玻璃体液样本中bFGF和VEGF水平,并使用临床数据和术中获得的数据对玻璃体视网膜纤维化程度进行特征描述。

结果

与非PDR(对照)受试者的眼睛相比,PDR患者的VEGF和bFGF水平显著升高(P < 0.01)。与未接受IVB治疗的PDR患者相比,IVB治疗后PDR患者的玻璃体内VEGF水平显著降低(P < 0.01)。与a组相比,b组的玻璃体视网膜纤维化程度显著增加(P < 0.05),与未接受IVB治疗的患者相比也显著增加(P < 0.05)。b组的玻璃体内bFGF水平显著高于a组(P < 0.01)或未接受IVB治疗的患者(P < 0.05)。Spearman等级相关检验表明,玻璃体内较高水平的bFGF而非VEGF与玻璃体视网膜纤维化程度相关。

结论

我们发现,在玻璃体切除术前超过两周接受IVB治疗的PDR患者玻璃体内,bFGF水平升高,且与IVB治疗后的纤维化程度相关。这些发现表明,IVB治疗后PDR患者的玻璃体纤维化增加可能是由于bFGF水平升高所致。

相似文献

1
Changes in vitreous VEGF, bFGF and fibrosis in proliferative diabetic retinopathy after intravitreal bevacizumab.
Int J Ophthalmol. 2015 Dec 18;8(6):1202-6. doi: 10.3980/j.issn.2222-3959.2015.06.22. eCollection 2015.
2
Optimal timing of preoperative intravitreal anti-VEGF injection for proliferative diabetic retinopathy patients.
Int J Ophthalmol. 2022 Oct 18;15(10):1619-1626. doi: 10.18240/ijo.2022.10.09. eCollection 2022.
5
Serum and vitreous vascular endothelial growth factor levels in diabetic retinopathy.
Int Ophthalmol. 2023 Jul;43(7):2247-2255. doi: 10.1007/s10792-022-02620-y. Epub 2022 Dec 29.
6
Preoperative Timing of Intravitreal Bevacizumab Injection for Proliferative Diabetic Retinopathy Patients.
Ophthalmic Res. 2018;60(4):250-257. doi: 10.1159/000493640. Epub 2018 Oct 31.

引用本文的文献

1
Human Antigen R -mediated modulation of Transforming Growth Factor Beta 1 expression in retinal pathological milieu.
Biochem Biophys Rep. 2024 Aug 12;39:101807. doi: 10.1016/j.bbrep.2024.101807. eCollection 2024 Sep.
2
Effects of aflibercept and bevacizumab on cell viability, cell metabolism and inflammation in hypoxic human Müller cells.
PLoS One. 2024 Mar 27;19(3):e0300370. doi: 10.1371/journal.pone.0300370. eCollection 2024.
3
Effect of a novel tyrosine kinase inhibitor nintedanib on bFGF and VEGF concentrations in a rabbit retinal vein occlusion model.
Int J Ophthalmol. 2023 Sep 18;16(9):1450-1455. doi: 10.18240/ijo.2023.09.11. eCollection 2023.
4
Anti-vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy.
Cochrane Database Syst Rev. 2023 May 31;5(5):CD008214. doi: 10.1002/14651858.CD008214.pub4.
5
Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.
Cochrane Database Syst Rev. 2023 Mar 20;3(3):CD008721. doi: 10.1002/14651858.CD008721.pub3.
6
Changes in the vitreous body after experimental vitreous hemorrhage in rabbit: An interdisciplinary study.
PLoS One. 2023 Feb 6;18(2):e0281165. doi: 10.1371/journal.pone.0281165. eCollection 2023.
9
Optimal timing of preoperative intravitreal anti-VEGF injection for proliferative diabetic retinopathy patients.
Int J Ophthalmol. 2022 Oct 18;15(10):1619-1626. doi: 10.18240/ijo.2022.10.09. eCollection 2022.
10
Mechanistic Pathogenesis of Endothelial Dysfunction in Diabetic Nephropathy and Retinopathy.
Front Endocrinol (Lausanne). 2022 May 25;13:816400. doi: 10.3389/fendo.2022.816400. eCollection 2022.

本文引用的文献

1
Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1.
Arch Ophthalmol. 2012 Sep;130(9):1127-34. doi: 10.1001/archophthalmol.2012.1611.
2
Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy.
J Diabetes Complications. 2012 Sep-Oct;26(5):435-41. doi: 10.1016/j.jdiacomp.2012.05.005. Epub 2012 Jun 12.
4
Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy.
Curr Eye Res. 2012 May;37(5):416-20. doi: 10.3109/02713683.2012.661114. Epub 2012 Mar 12.
5
Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy.
Br J Ophthalmol. 2011 Dec;95(12):1631-7. doi: 10.1136/bjo.2010.186361. Epub 2011 May 5.
7
Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications.
Ophthalmology. 2011 Apr;118(4):636-41. doi: 10.1016/j.ophtha.2010.08.038. Epub 2010 Nov 4.
8
Development of subretinal fibrosis after anti-VEGF treatment in neovascular age-related macular degeneration.
Ophthalmic Surg Lasers Imaging. 2011 Jan-Feb;42(1):6-11. doi: 10.3928/15428877-20100924-01. Epub 2010 Sep 29.
9
Diabetic retinopathy.
Lancet. 2010 Jul 10;376(9735):124-36. doi: 10.1016/S0140-6736(09)62124-3. Epub 2010 Jun 26.
10
Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy.
Graefes Arch Clin Exp Ophthalmol. 2010 Jun;248(6):785-91. doi: 10.1007/s00417-010-1303-3. Epub 2010 Feb 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验